• Je něco špatně v tomto záznamu ?

Discovery of varlaxins, new aeruginosin-type inhibitors of human trypsins

LMP. Heinilä, J. Jokela, MN. Ahmed, M. Wahlsten, S. Kumar, P. Hrouzek, P. Permi, H. Koistinen, DP. Fewer, K. Sivonen

. 2022 ; 20 (13) : 2681-2692. [pub] 20220330

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019099

Low-molecular weight natural products display vast structural diversity and have played a key role in the development of novel therapeutics. Here we report the discovery of novel members of the aeruginosin family of natural products, which we named varlaxins. The chemical structures of varlaxins 1046A and 1022A were determined using a combination of mass spectrometry, analysis of one- and two-dimensional NMR spectra, and HPLC analysis of Marfey's derivatives. These analyses revealed that varlaxins 1046A and 1022A are composed of the following moieties: 2-O-methylglyceric acid 3-O-sulfate, isoleucine, 2-carboxy-6-hydroxyoctahydroindole (Choi), and a terminal arginine derivative. Varlaxins 1046A and 1022A differ in the cyclization of this arginine moiety. Interestingly, an unusual α-D-glucopyranose moiety derivatized with two 4-hydroxyphenylacetic acid residues was bound to Choi, a structure not previously reported for other members of the aeruginosin family. We sequenced the complete genome of Nostoc sp. UHCC 0870 and identified the putative 36 kb varlaxin biosynthetic gene cluster. Bioinformatics analysis confirmed that varlaxins belong to the aeruginosin family of natural products. Varlaxins 1046A and 1022A strongly inhibited the three human trypsin isoenzymes with IC50 of 0.62-3.6 nM and 97-230 nM, respectively, including a prometastatic trypsin-3, which is a therapeutically relevant target in several types of cancer. These results substantially broaden the genetic and chemical diversity of the aeruginosin family and provide evidence that the aeruginosin family is a source of strong inhibitors of human serine proteases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019099
003      
CZ-PrNML
005      
20220804135347.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1039/d1ob02454j $2 doi
035    __
$a (PubMed)35293909
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Heinilä, L M P $u Department of Microbiology, Faculty of Agriculture and Forestry, University of Helsinki, Helsinki, Finland. david.fewer@helsinki.fi $1 https://orcid.org/0000000325580091
245    10
$a Discovery of varlaxins, new aeruginosin-type inhibitors of human trypsins / $c LMP. Heinilä, J. Jokela, MN. Ahmed, M. Wahlsten, S. Kumar, P. Hrouzek, P. Permi, H. Koistinen, DP. Fewer, K. Sivonen
520    9_
$a Low-molecular weight natural products display vast structural diversity and have played a key role in the development of novel therapeutics. Here we report the discovery of novel members of the aeruginosin family of natural products, which we named varlaxins. The chemical structures of varlaxins 1046A and 1022A were determined using a combination of mass spectrometry, analysis of one- and two-dimensional NMR spectra, and HPLC analysis of Marfey's derivatives. These analyses revealed that varlaxins 1046A and 1022A are composed of the following moieties: 2-O-methylglyceric acid 3-O-sulfate, isoleucine, 2-carboxy-6-hydroxyoctahydroindole (Choi), and a terminal arginine derivative. Varlaxins 1046A and 1022A differ in the cyclization of this arginine moiety. Interestingly, an unusual α-D-glucopyranose moiety derivatized with two 4-hydroxyphenylacetic acid residues was bound to Choi, a structure not previously reported for other members of the aeruginosin family. We sequenced the complete genome of Nostoc sp. UHCC 0870 and identified the putative 36 kb varlaxin biosynthetic gene cluster. Bioinformatics analysis confirmed that varlaxins belong to the aeruginosin family of natural products. Varlaxins 1046A and 1022A strongly inhibited the three human trypsin isoenzymes with IC50 of 0.62-3.6 nM and 97-230 nM, respectively, including a prometastatic trypsin-3, which is a therapeutically relevant target in several types of cancer. These results substantially broaden the genetic and chemical diversity of the aeruginosin family and provide evidence that the aeruginosin family is a source of strong inhibitors of human serine proteases.
650    _2
$a arginin $7 D001120
650    12
$a biologické přípravky $x farmakologie $7 D001688
650    _2
$a vysokoúčinná kapalinová chromatografie $7 D002851
650    _2
$a lidé $7 D006801
650    _2
$a molekulární struktura $7 D015394
650    _2
$a trypsin $7 D014357
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jokela, J $u Department of Microbiology, Faculty of Agriculture and Forestry, University of Helsinki, Helsinki, Finland. david.fewer@helsinki.fi
700    1_
$a Ahmed, M N $u Department of Microbiology, Faculty of Agriculture and Forestry, University of Helsinki, Helsinki, Finland. david.fewer@helsinki.fi $u Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland $1 https://orcid.org/000000023768873X
700    1_
$a Wahlsten, M $u Department of Microbiology, Faculty of Agriculture and Forestry, University of Helsinki, Helsinki, Finland. david.fewer@helsinki.fi $1 https://orcid.org/0000000241071695
700    1_
$a Kumar, S $u Laboratory of Algal Biotechnology-Centre Algatech, Institute of Microbiology of the Czech Academy of Sciences, Třeboň, Czech Republic $1 https://orcid.org/0000000270844204
700    1_
$a Hrouzek, P $u Laboratory of Algal Biotechnology-Centre Algatech, Institute of Microbiology of the Czech Academy of Sciences, Třeboň, Czech Republic $1 https://orcid.org/0000000220610266
700    1_
$a Permi, P $u Department of Chemistry, University of Jyväskylä, Jyväskylä, Finland $u Department of Biological and Environmental Science, Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland
700    1_
$a Koistinen, H $u Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland $1 https://orcid.org/0000000309263109
700    1_
$a Fewer, D P $u Department of Microbiology, Faculty of Agriculture and Forestry, University of Helsinki, Helsinki, Finland. david.fewer@helsinki.fi $1 https://orcid.org/0000000339784845
700    1_
$a Sivonen, K $u Department of Microbiology, Faculty of Agriculture and Forestry, University of Helsinki, Helsinki, Finland. david.fewer@helsinki.fi $1 https://orcid.org/0000000229040458
773    0_
$w MED00007088 $t Organic & biomolecular chemistry $x 1477-0539 $g Roč. 20, č. 13 (2022), s. 2681-2692
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35293909 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135341 $b ABA008
999    __
$a ok $b bmc $g 1822631 $s 1170342
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 20 $c 13 $d 2681-2692 $e 20220330 $i 1477-0539 $m Organic & biomolecular chemistry $n Org Biomol Chem $x MED00007088
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace